Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pablo Barreiro

Showing results (141-150 of 220) with videos related to

Pageof 22
Sort By:
Liver International : Official Journal of the International Association for the Study of the Liver|June 5, 2013
Scaling up epidemics of acute hepatitis C and syphilis in HIV-infected men who have sex with men in SpainClara Sánchez, Zulema Plaza, Eugenia Vispo, et al.
Expert Opinion on Drug Safety|July 28, 2015
Dual antiviral therapy for HIV and hepatitis C - drug interactions and side effectsIsabella Esposito, Pablo Labarga, Pablo Barreiro, et al.
AIDS Reviews|December 13, 2023
Pre-exposure prophylaxis of non-HIV viral infections and the role of long-acting antiviralsVicente Soriano, Víctor Moreno-Torres, Carmen de Mendoza, et al.
Antiviral Therapy|June 28, 2013
Very late relapse after discontinuation of antiviral therapy for chronic hepatitis CVincent Soriano, Eugenia Vispo, Carmen de Mendoza, et al.
Antiviral Therapy|October 1, 2004
Hepatitis C virus-RNA clearance in HIV-coinfected patients with chronic hepatitis C treated with pegylated interferon plus ribavirinVincent Soriano, Marina Núñez, Nuria Camino, et al.
Expert Opinion on Drug Safety|June 17, 2017
Dual antiretroviral therapy for HIV infectionVicente Soriano, Jose Vicente Fernandez-Montero, Laura Benitez-Gutierrez, et al.
Expert Opinion on Drug Metabolism & Toxicology|January 3, 2015
Drug interactions with new hepatitis C oral drugsVincent Soriano, Pablo Labarga, Pablo Barreiro, et al.
Antiviral Research|November 14, 2012
The changing face of hepatitis C in the new era of direct-acting antiviralsVincent Soriano, Pablo Labarga, Jose V Fernández-Montero, et al.
Therapeutic Drug Monitoring|March 11, 2010
The benefit of simplification from tipranavir/ritonavir 500/200 bid to 500/100 bid guided by therapeutic drug monitoringJudit Morello, Sonia Rodríguez-Novoa, Francisco Blanco, et al.
Journal of Viral Hepatitis|June 1, 2022
Hepatitis C hospitalizations in Spain and impact of new curative antiviral therapiesJosé-Manuel Ramos-Rincon, Héctor Pinargote-Celorio, Carmen de Mendoza, et al.
Pageof 22

Showing results (141-150 of 220) with videos related to

Sort By:
Pageof 22
Liver International : Official Journal of the International Association for the Study of the Liver|June 5, 2013
Scaling up epidemics of acute hepatitis C and syphilis in HIV-infected men who have sex with men in SpainClara Sánchez, Zulema Plaza, Eugenia Vispo, et al.
Expert Opinion on Drug Safety|July 28, 2015
Dual antiviral therapy for HIV and hepatitis C - drug interactions and side effectsIsabella Esposito, Pablo Labarga, Pablo Barreiro, et al.
AIDS Reviews|December 13, 2023
Pre-exposure prophylaxis of non-HIV viral infections and the role of long-acting antiviralsVicente Soriano, Víctor Moreno-Torres, Carmen de Mendoza, et al.
Antiviral Therapy|June 28, 2013
Very late relapse after discontinuation of antiviral therapy for chronic hepatitis CVincent Soriano, Eugenia Vispo, Carmen de Mendoza, et al.
Antiviral Therapy|October 1, 2004
Hepatitis C virus-RNA clearance in HIV-coinfected patients with chronic hepatitis C treated with pegylated interferon plus ribavirinVincent Soriano, Marina Núñez, Nuria Camino, et al.
Expert Opinion on Drug Safety|June 17, 2017
Dual antiretroviral therapy for HIV infectionVicente Soriano, Jose Vicente Fernandez-Montero, Laura Benitez-Gutierrez, et al.
Expert Opinion on Drug Metabolism & Toxicology|January 3, 2015
Drug interactions with new hepatitis C oral drugsVincent Soriano, Pablo Labarga, Pablo Barreiro, et al.
Antiviral Research|November 14, 2012
The changing face of hepatitis C in the new era of direct-acting antiviralsVincent Soriano, Pablo Labarga, Jose V Fernández-Montero, et al.
Therapeutic Drug Monitoring|March 11, 2010
The benefit of simplification from tipranavir/ritonavir 500/200 bid to 500/100 bid guided by therapeutic drug monitoringJudit Morello, Sonia Rodríguez-Novoa, Francisco Blanco, et al.
Journal of Viral Hepatitis|June 1, 2022
Hepatitis C hospitalizations in Spain and impact of new curative antiviral therapiesJosé-Manuel Ramos-Rincon, Héctor Pinargote-Celorio, Carmen de Mendoza, et al.
Pageof 22